Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

740

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG: Datopotamab Deruxtecan
DRUG: Pembrolizumab

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]